Nuvectis Pharma, Inc.
NVCTAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 1, 2026 | Loop Capital Markets | Elemer Piros | $40.00(+76%) | $22.73 | StreetInsider |
| Jul 6, 2026 | UBS | $33.00(+69%) | $19.57 | TheFly | |
| Jun 22, 2026 | H.C. Wainwright | $39.00(+161%) | $14.96 | TheFly | |
| Jun 12, 2026 | H.C. Wainwright | $13.00(+22%) | $10.67 | TheFly | |
| Aug 4, 2025 | H.C. Wainwright | $10.00(+37%) | $7.29 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 24, 2026 |
| Roth Capital | maintain | Buy | Jul 6, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 22, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 12, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 4, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 30, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 7, 2023 |
| HC Wainwright & Co. | maintain | Buy | Feb 10, 2023 |
| Ladenburg Thalmann | maintain | Buy | Jul 13, 2022 |
| HC Wainwright & Co. | maintain | Buy | May 10, 2022 |
| HC Wainwright & Co. | maintain | Buy | Mar 2, 2022 |
Earnings History
Next report: Feb 10, 2027 · EPS est. $-0.26| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 4, 2026 | $-1.02 | $-0.24 | — | — |
| Aug 4, 2026 | $-0.30 | $-0.26 | — | — |
| May 5, 2026 | $-0.26 | $-0.30 | — | — |
| Feb 11, 2026 | $-0.31 | $-0.26 | — | — |
| Nov 4, 2025 | $-0.44 | $-0.24 | — | — |
| Aug 5, 2025 | $-0.30 | $-0.25 | — | — |
| May 6, 2025 | $-0.27 | $-0.30 | — | — |
| Feb 25, 2025 | $-0.36 | $-0.28 | — | — |
News
Nuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call Transcript
Nuvectis Pharma NASDAQ: NVCT said its third quarter marked a strategic shift into late-stage development following a licensing agreement with Haisco for ex-China rights to two drug candidates: ciprocopan, also known as NXP100, and NXP200.
In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical development company. The Company's lead drug candidate, ciprocopan (NXP100), a Complement Factor B inhibitor (CFBi) for once-daily oral administration, was approved in China in July 2026 for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) previously untreated with complement inhibitors.
Fort Lee, NJ, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that it will host a conference call and webcast on Wednesday, November 4, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026.
Single-agent NXP200 was administered to 27 patients with recurrent or progressive gliomas (20 with high-grade and 7 with low-grade). The objective response rate (ORR) based on Response Assessment in Neuro-Oncology criteria (RANO) 2.0 was 40.0% (8/20) in high-grade glioma, including 3 Complete Responses (CRs), and 42.9% (3/7) in low-grade glioma, including 1 CR.
Nuvectis Pharma, Inc. (NASDAQ: NVCT - Get Free Report)'s stock price gapped up prior to trading on Monday. The stock had previously closed at $20.13, but opened at $21.12. Nuvectis Pharma shares last traded at $21.20, with a volume of 1,499 shares changing hands. Analyst Ratings Changes A number of equities research analysts have recently weighed
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026 in New York.
Shares of Nuvectis Pharma, Inc. (NASDAQ: NVCT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a
Fort Lee, NJ, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, announced today that NXP200 (HSK42360), an oral, brain-penetrant, paradox-breaker BRAF inhibitor, has been granted Breakthrough Therapy Designation (BTD) for the treatment of patients with BRAF V600-mutant, recurrent or prog…
BlackRock Inc. bought a new position in shares of Nuvectis Pharma, Inc. (NASDAQ: NVCT) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 1,001,285 shares of the company's stock, valued at approximately $18,414,000. BlackRock Inc. owned approximately 3.07% of Nuvectis
Fort Lee, NJ, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference: Fireside Chat, Friday, September 11, 2026 at 9:10 AM ET.
NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.